Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Rep ; 11(1): 525, 2021 01 12.
Article in English | MEDLINE | ID: mdl-33436854

ABSTRACT

Many therapeutic drugs are compounds that can be represented by simple chemical structures, which contain important determinants of affinity at the site of action. Recently, graph convolutional neural network (GCN) models have exhibited excellent results in classifying the activity of such compounds. For models that make quantitative predictions of activity, more complex information has been utilized, such as the three-dimensional structures of compounds and the amino acid sequences of their respective target proteins. As another approach, we hypothesized that if sufficient experimental data were available and there were enough nodes in hidden layers, a simple compound representation would quantitatively predict activity with satisfactory accuracy. In this study, we report that GCN models constructed solely from the two-dimensional structural information of compounds demonstrated a high degree of activity predictability against 127 diverse targets from the ChEMBL database. Using the information entropy as a metric, we also show that the structural diversity had less effect on the prediction performance. Finally, we report that virtual screening using the constructed model identified a new serotonin transporter inhibitor with activity comparable to that of a marketed drug in vitro and exhibited antidepressant effects in behavioural studies.


Subject(s)
Neural Networks, Computer , Pharmaceutical Preparations/chemistry , Pharmacology , Amino Acid Sequence , Antidepressive Agents , Drug Evaluation, Preclinical/methods , Humans , Molecular Conformation , Selective Serotonin Reuptake Inhibitors
2.
Brain Res ; 1719: 243-252, 2019 09 15.
Article in English | MEDLINE | ID: mdl-31194947

ABSTRACT

Serotonin (5-HT) in the central nervous system regulates a variety of biological functions, from the basic homeostatic control to higher brain functions, by acting on fourteen known receptor subtypes. However, it is still usually unclear which receptor subtype is responsible for a specific function due to the lack of highly selective ligands for most of these receptors. Although 5-HT receptor knockout mice are useful, the brain-wide distribution of various receptors makes it difficult to dissect receptor functions in specific and brain regions and cell types. Recent advances in CRISPR/Cas9-mediated in vivo genome editing technology may overcome this problem. In this study, we constructed a viral vector expressing a single guide (sg)RNA targeting Htr1a (sgHtr1a) and Cre recombinase under the control of a neuron-specific promoter. Injection of the viral vector into the dorsal raphe nucleus (DRN) of Cre-dependent Cas9 knock-in mice induced Cre-dependent Cas9 expression mainly in DRN serotonin and GABA neurons. Mismatch cleavage assay and Sanger sequencing showed insertion or deletion formation at the target site. 5-HT1A receptor agonist-induced hypothermia was attenuated and antidepressant effect of a selective serotonin reuptake inhibitor (SSRI) was enhanced by microinjection of the viral vector expressing sgHtr1a into the DRN of Cre-dependent Cas9 knock-in mice. These results suggest that this in vivo CRISPR/Cas9-mediated 5-HT receptor gene knockout strategy provides a reliable and low-cost method for elucidating 5-HT receptor functions in specific cell types and brain regions. Further, we demonstrate that the neuronal 5-HT1A receptor in the DRN regulates body temperature and antidepressant effect of SSRI.


Subject(s)
Body Temperature Regulation/genetics , Dorsal Raphe Nucleus/physiology , Receptor, Serotonin, 5-HT1A/genetics , Animals , Body Temperature Regulation/physiology , CRISPR-Cas Systems/genetics , Dorsal Raphe Nucleus/metabolism , Female , Gene Editing/methods , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Neural Inhibition/physiology , Receptor, Serotonin, 5-HT1A/metabolism , Receptors, Serotonin/metabolism , Serotonergic Neurons/metabolism , Serotonin/metabolism , Serotonin Antagonists/pharmacology , Serotonin Receptor Agonists/pharmacology , Selective Serotonin Reuptake Inhibitors/pharmacology
3.
Neuropsychopharmacology ; 44(4): 721-732, 2019 03.
Article in English | MEDLINE | ID: mdl-30377380

ABSTRACT

Major depression and anxiety disorders are a social and economic burden worldwide. Serotonergic signaling has been implicated in the pathophysiology of these disorders and thus has been a crucial target for pharmacotherapy. However, the precise mechanisms underlying these disorders are still unclear. Here, we used species-optimized lentiviral vectors that were capable of efficient and specific transduction of serotonergic neurons in mice and rats for elucidation of serotonergic roles in anxiety-like behaviors and active coping behavior in both species. Immunohistochemical analyses revealed that lentiviral vectors with an upstream sequence of tryptophan hydroxylase 2 gene efficiently transduced serotonergic neurons with a specificity of approximately 95% in both mice and rats. Electrophysiological recordings showed that these lentiviral vectors induced sufficient expression of optogenetic tools for precise control of serotonergic neurons. Using these vectors, we demonstrate that acute activation of serotonergic neurons in the dorsal raphe nucleus increases active coping with inescapable stress in rats and mice in a time-locked manner, and that acute inhibition of these neurons increases anxiety-like behaviors specifically in rats. These findings further our understanding of the pathophysiological role of dorsal raphe serotonergic neurons in different species and the role of these neurons as therapeutic targets in major depression and anxiety disorders.


Subject(s)
Adaptation, Psychological/physiology , Anxiety/physiopathology , Behavior, Animal/physiology , Dorsal Raphe Nucleus/physiology , Serotonergic Neurons/physiology , Animals , Disease Models, Animal , Electrophysiological Phenomena , Genetic Vectors , Lentivirus , Male , Mice , Mice, Inbred C57BL , Optogenetics , Rats , Rats, Wistar
4.
Int J Neuropsychopharmacol ; 21(3): 305-310, 2018 03 01.
Article in English | MEDLINE | ID: mdl-29370396

ABSTRACT

Background: Ketamine rapidly elicits antidepressive effects in humans and mice in which serotonergic activity is involved. Although α4ß2 nicotinic acetylcholine receptor (α4ß2 nAChR) in the dorsal raphe nucleus plays a key role in the ketamine-induced prefrontal serotonin release, the source of cholinergic afferents, and its role is unclear. Methods: Prefrontal serotonin levels after ketamine injection were measured by microdialysis in rats. Electrolytic lesion of pedunculopontine tegmental nucleus and laterodorsal tegmental nucleus was made with constant direct current. Results: Bilateral lesion of the pedunculopontine tegmental nucleus, but not laterodorsal tegmental nucleus, attenuated prefrontal serotonin release induced by systemic ketamine. Intra-pedunculopontine tegmental nucleus, but not intra-laterodorsal tegmental nucleus ketamine perfusion, increased prefrontal serotonin release. This increase was attenuated by intra-dorsal raphe nucleus injection of dihydro-ß-erythroidine, an α4ß2 nAChR antagonist, or NBQX, an AMPA receptor antagonist. Conclusions: These results suggest the ketamine-induced serotonin release in medial prefrontal cortex is mediated by cholinergic neurons projecting from pedunculopontine tegmental nucleus to dorsal raphe nucleus via α4ß2 nAChRs.


Subject(s)
Antidepressive Agents/pharmacology , Cholinergic Neurons/drug effects , Ketamine/pharmacology , Pedunculopontine Tegmental Nucleus/drug effects , Prefrontal Cortex/drug effects , Serotonin/metabolism , Animals , Cholinergic Neurons/metabolism , Male , Neurotransmitter Agents/pharmacology , Pedunculopontine Tegmental Nucleus/metabolism , Prefrontal Cortex/metabolism , Rats, Wistar , Receptors, AMPA/antagonists & inhibitors , Receptors, AMPA/metabolism , Receptors, Nicotinic/metabolism
5.
Sci Rep ; 7(1): 13609, 2017 10 19.
Article in English | MEDLINE | ID: mdl-29051549

ABSTRACT

Spontaneous activity of serotonergic neurons of the dorsal raphe nucleus (DRN) regulates mood and motivational state. Potentiation of serotonergic function is one of the therapeutic strategies for treatment of various psychiatric disorders, such as major depression, panic disorder and obsessive-compulsive disorder. However, the control mechanisms of the serotonergic firing activity are still unknown. In this study, we examined the control mechanisms for serotonergic spontaneous activity and effects of chronic antidepressant administration on these mechanisms by using modified ex vivo electrophysiological recording methods. Serotonergic neurons remained firing even in the absence of glutamatergic and GABAergic ionotropic inputs, while blockade of L-type voltage dependent Ca2+ channels (VDCCs) in serotonergic neurons decreased spontaneous firing activity. L-type VDCCs in serotonergic neurons received gamma-aminobutyric acid B (GABAB) receptor-mediated inhibition, which maintained serotonergic slow spontaneous firing activity. Chronic administration of an antidepressant, citalopram, disinhibited the serotonergic spontaneous firing activity by weakening the GABAB receptor-mediated inhibition of L-type VDCCs in serotonergic neurons. Our results provide a new mechanism underlying the spontaneous serotonergic activity and new insights into the mechanism of action of antidepressants.


Subject(s)
Antidepressive Agents/pharmacology , Calcium Channels, L-Type/metabolism , Receptors, GABA-B/metabolism , Serotonergic Neurons/drug effects , 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester/pharmacology , Action Potentials/drug effects , Animals , Calcium Channels, L-Type/chemistry , Citalopram/pharmacology , Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors , Cyclic AMP-Dependent Protein Kinases/metabolism , In Vitro Techniques , Male , Mice , Mice, Inbred C57BL , Patch-Clamp Techniques , Receptors, GABA-B/chemistry , Serotonergic Neurons/physiology
6.
J Toxicol Sci ; 41(6): 813-816, 2016.
Article in English | MEDLINE | ID: mdl-27853110

ABSTRACT

N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-3-methyl-D-valine methyl ester (5F-ADB) is one of the most potent synthetic cannabinoids and elicits severe psychotic symptoms in humans, sometimes causing death. To investigate the neuronal mechanisms underlying its toxicity, we examined the effects of 5F-ADB on midbrain dopaminergic and serotonergic systems, which modulate various basic brain functions such as those in reward-related behavior. 5F-ADB-induced changes in spontaneous firing activity of dopaminergic and serotonergic neurons were recorded by ex vivo electrophysiological techniques. In dopaminergic neurons, 5F-ADB (1 µM) significantly increased the spontaneous firing rate, while 5F-ADB failed to activate dopaminergic neurons in the presence of the CB1 antagonist AM251 (1 µM). However, the same concentration of 5F-ADB did not affect serotonergic-neuron activity. These results suggest that 5F-ADB activates local CB1 receptors and potentiates midbrain dopaminergic systems with no direct effects on midbrain serotonergic systems.


Subject(s)
Cannabinoid Receptor Agonists/toxicity , Cannabinoids/toxicity , Designer Drugs/toxicity , Dopaminergic Neurons/drug effects , Mesencephalon/drug effects , Serotonergic Neurons/drug effects , Action Potentials , Animals , Cannabinoid Receptor Agonists/chemical synthesis , Cannabinoids/chemical synthesis , Designer Drugs/chemical synthesis , Dopaminergic Neurons/metabolism , In Vitro Techniques , Male , Mesencephalon/metabolism , Mice, Inbred C57BL , Receptor, Cannabinoid, CB1/agonists , Receptor, Cannabinoid, CB1/metabolism , Serotonergic Neurons/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...